{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:10:26Z","timestamp":1794705026731,"version":"4.9.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>\n                    A number of common driver mutations have been identified in melanoma, but other genetic or epigenetic aberrations are also likely to play a role in the pathogenesis of melanoma and present potential therapeutic targets. Translocations of the anaplastic lymphoma kinase (\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    ), for example, have been reported in spitzoid melanocytic neoplasms leading to kinase-fusion proteins that result in immunohistochemically detectable\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    expression. In this study, we sought to determine whether\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    was also expressed in nonspitzoid primary and metastatic cutaneous melanomas. ALK immunohistochemistry was performed on 603 melanomas (303 primary and 300 metastatic tumors) from 600 patients. ALK immunohistochemistry expression was identified in 7 primary and 9 metastatic tumors. In 5 of 7 primary tumors and in 6 of 9 metastatic lesions, the majority of tumor cells were immunoreactive for ALK. In the other 2 primary and 3 metastatic lesions, positive staining was identified in less than half of the tumor cells. ALK positivity was found in the presence or absence of\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    or\n                    <jats:italic toggle=\"yes\">NRAS<\/jats:italic>\n                    mutations. In contrast to prior observations with ALK-positive Spitz tumors, none of the ALK-positive melanomas harbored a translocation. Instead, the ALK-positive melanomas predominantly expressed the recently described\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    isoform,\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    <jats:sup>ATI<\/jats:sup>\n                    , which lacks the extracellular and transmembrane domains of wild-type\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    , consists primarily of the intracellular tyrosine kinase domain, and originates from an alternative transcriptional initiation site within the\n                    <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                    gene. The findings are clinically relevant as patients with metastatic melanoma who have ALK expression may potentially benefit from treatment with ALK kinase inhibitors.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000000611","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T09:07:18Z","timestamp":1455268038000},"page":"786-795","source":"Crossref","is-referenced-by-count":46,"title":["Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation"],"prefix":"10.1097","volume":"40","author":[{"given":"Klaus J.","family":"Busam","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo E.","family":"Vilain","sequence":"additional","affiliation":[{"name":"Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown"},{"name":"Melanoma Institute of Australia, North Sydney"},{"name":"Sydney Medical School, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trina","family":"Lum","sequence":"additional","affiliation":[{"name":"Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Busam","sequence":"additional","affiliation":[{"name":"Dartmouth College, Hanover, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis J.","family":"Hollmann","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn P.M.","family":"Saw","sequence":"additional","affiliation":[{"name":"Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown"},{"name":"Melanoma Institute of Australia, North Sydney"},{"name":"Sydney Medical School, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Coit","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[{"name":"Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown"},{"name":"Melanoma Institute of Australia, North Sydney"},{"name":"Sydney Medical School, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1158\/1078-0432.CCR-14-0058","article-title":"Melanoma BRAF fusions\u2014letter","volume":"20","author":"Botton","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/pcmr.12148","article-title":"Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy","volume":"26","author":"Botton","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm.2166","article-title":"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma","volume":"16","author":"Palanisamy","year":"2010","journal-title":"Nat Med"},{"key":"R9-20230922","article-title":"Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma","author":"Wilson","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/archderm.137.11.1507","article-title":"Genomic approaches to skin cancer diagnosis","volume":"137","author":"Bastian","year":"2001","journal-title":"Arch Dermatol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1523-1747.1999.00787.x","article-title":"Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma","volume":"113","author":"Bastian","year":"1999","journal-title":"J Invest Dermatol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yadr.2005.04.002","article-title":"Genomic analysis of melanocytic neoplasia","volume":"21","author":"Bauer","year":"2005","journal-title":"Adv Dermatol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/PAS.0000000000000387","article-title":"Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions","volume":"39","author":"Yeh","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAS.0b013e3181c7d8b2","article-title":"Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma","volume":"34","author":"Hantschke","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/cup.12197","article-title":"Compound clear cell sarcoma misdiagnosed as a Spitz nevus","volume":"40","author":"Kiuru","year":"2013","journal-title":"J Cutan Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2407-11-380","article-title":"EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation","volume":"11","author":"Neumann","year":"2011","journal-title":"BMC Cancer"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature15258","article-title":"Alternative transcription initiation leads to expression of a novel ALK isoform in cancer","volume":"526","author":"Wiesner","year":"2015","journal-title":"Nature"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0002-9440(10)64609-3","article-title":"Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features","volume":"157","author":"Bastian","year":"2000","journal-title":"Am J Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1038\/ncomms8174","article-title":"Activating MET kinase rearrangements in melanoma and Spitz tumours","volume":"6","author":"Yeh","year":"2015","journal-title":"Nat Commun"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3390\/cancers7030864","article-title":"The evolution of therapies in non-small cell lung cancer","volume":"7","author":"Boolell","year":"2015","journal-title":"Cancers"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrclinonc.2012.72","article-title":"in neuroblastoma\u2014preclinical and clinical advancements","volume":"9","author":"Carpenter","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-20230922","first-page":"282","article-title":"Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer","volume":"13","author":"Shaw","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcb.24401","article-title":"Molecular diagnostics and personalized medicine in oncology: challenges and opportunities","volume":"114","author":"Normanno","year":"2013","journal-title":"J Cell Biochem"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-08-2762","article-title":"Inhibition of ALK signaling for cancer therapy","volume":"15","author":"Mosse","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nbt1385","article-title":"Direct multiplexed measurement of gene expression with color-coded probe pairs","volume":"26","author":"Geiss","year":"2008","journal-title":"Nat Biotechnol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1472-6750-11-46","article-title":"mRNA transcript quantification in archival samples using multiplexed, color-coded probes","volume":"11","author":"Reis","year":"2011","journal-title":"BMC Biotechnol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"395","DOI":"10.6004\/jnccn.2013.0055","article-title":"Melanoma, version 2.2013: featured updates to the NCCN guidelines","volume":"11","author":"Coit","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14656566.2013.770475","article-title":"Trametinib (GSK1120212) in the treatment of melanoma","volume":"14","author":"Salama","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"R31-20230922","first-page":"21","article-title":"Dabrafenib for treatment of BRAF-mutant melanoma","volume":"7","author":"Kainthla","year":"2014","journal-title":"Pharmacogenomics Pers Med"},{"key":"R32-20230922","first-page":"243","article-title":"Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma","volume":"4","author":"Fisher","year":"2012","journal-title":"Cancer Manag Res"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PPO.0000000000000024","article-title":"A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States","volume":"20","author":"Flaherty","year":"2014","journal-title":"Cancer J"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejca.2015.04.010","article-title":"Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression","volume":"51","author":"Puzanov","year":"2015","journal-title":"Eur J Cancer"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ng.3382","article-title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway","volume":"47","author":"Shain","year":"2015","journal-title":"Nat Genet"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/cgt.2015.39","article-title":"A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance","volume":"22","author":"Dietel","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/PAS.0000000000000187","article-title":"Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions","volume":"38","author":"Busam","year":"2014","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201606000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T18:21:18Z","timestamp":1695406878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201606000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000611","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726141625.793519578","asserted-by":"object"}]},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}